Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score.

Souza-Nogueira A, Camargo AE, Remondi FA, Paoliello MM, Richter RJ, Furlong CE, Barbosa DS, Maes M, Moreira EG.

Arch Endocrinol Metab. 2016 Oct;60(5):426-435. doi: 10.1590/2359-3997000000184. Epub 2016 Aug 25.

2.

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.

Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE.

PLoS One. 2014 Oct 15;9(10):e110054. doi: 10.1371/journal.pone.0110054. eCollection 2014.

3.

Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures.

Marsillach J, Hsieh EJ, Richter RJ, MacCoss MJ, Furlong CE.

Chem Biol Interact. 2013 Mar 25;203(1):85-90. doi: 10.1016/j.cbi.2012.10.019. Epub 2012 Nov 2.

4.

Dietary cholesterol increases paraoxonase 1 enzyme activity.

Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Nakayama KS, Jarvik ER, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP.

J Lipid Res. 2012 Nov;53(11):2450-8. doi: 10.1194/jlr.P030601. Epub 2012 Aug 15.

5.

Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease.

Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP.

J Lipids. 2012;2012:476316. doi: 10.1155/2012/476316. Epub 2012 May 22.

6.

Biomarkers of organophosphorus (OP) exposures in humans.

Marsillach J, Richter RJ, Kim JH, Stevens RC, MacCoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE.

Neurotoxicology. 2011 Oct;32(5):656-60. doi: 10.1016/j.neuro.2011.06.005. Epub 2011 Jul 8.

7.

Human PON1, a biomarker of risk of disease and exposure.

Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP.

Chem Biol Interact. 2010 Sep 6;187(1-3):355-61. doi: 10.1016/j.cbi.2010.03.033. Epub 2010 Mar 23. Review.

8.

Identification and characterization of biomarkers of organophosphorus exposures in humans.

Kim JH, Stevens RC, MacCoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE.

Adv Exp Med Biol. 2010;660:61-71. doi: 10.1007/978-1-60761-350-3_7. Review.

9.

Engineering human PON1 in an E. coli expression system.

Suzuki SM, Stevens RC, Richter RJ, Cole TB, Park S, Otto TC, Cerasoli DM, Lenz DE, Furlong CE.

Adv Exp Med Biol. 2010;660:37-45. doi: 10.1007/978-1-60761-350-3_5.

10.

Paraoxonase 1 status as a risk factor for disease or exposure.

Richter RJ, Jarvik GP, Furlong CE.

Adv Exp Med Biol. 2010;660:29-35. doi: 10.1007/978-1-60761-350-3_4. Review.

11.

Biomarkers of sensitivity and exposure in Washington state pesticide handlers.

Hofmann JN, Keifer MC, Checkoway H, De Roos AJ, Farin FM, Fenske RA, Richter RJ, van Belle G, Furlong CE.

Adv Exp Med Biol. 2010;660:19-27. doi: 10.1007/978-1-60761-350-3_3.

12.

Determination of paraoxonase 1 status without the use of toxic organophosphate substrates.

Richter RJ, Jarvik GP, Furlong CE.

Circ Cardiovasc Genet. 2008 Dec;1(2):147-52. doi: 10.1161/CIRCGENETICS.108.811638. No abstract available.

13.

Paraoxonase 1 (PON1) status and substrate hydrolysis.

Richter RJ, Jarvik GP, Furlong CE.

Toxicol Appl Pharmacol. 2009 Feb 15;235(1):1-9. doi: 10.1016/j.taap.2008.11.001. Epub 2008 Nov 13.

14.

Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning.

Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12780-4. doi: 10.1073/pnas.0805865105. Epub 2008 Aug 18.

15.

Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS.

Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, Cudkowicz ME, Furlong CE, Brown RH Jr.

Neurology. 2008 Mar 18;70(12):929-34. doi: 10.1212/01.wnl.0000305956.37931.dd.

PMID:
18347314
16.

PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity.

Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B.

Pharmacogenet Genomics. 2006 Mar;16(3):183-90.

PMID:
16495777
17.

TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease.

Carlson CS, Heagerty PJ, Hatsukami TS, Richter RJ, Ranchalis J, Lewis J, Bacus TJ, McKinstry LA, Schellenberg GD, Rieder M, Nickerson D, Furlong CE, Chait A, Jarvik GP.

J Lipid Res. 2006 May;47(5):1014-24. Epub 2006 Feb 11.

18.

Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants.

Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG.

Neurotoxicology. 2005 Aug;26(4):651-9. Review.

PMID:
16112327
19.

Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism.

Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE.

Pharmacogenet Genomics. 2005 Aug;15(8):589-98.

PMID:
16007003
20.

The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status.

Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, Gortner DA, Boyko E, Schellenberg GD, Furlong CE, Jarvik GP.

J Lipid Res. 2005 Sep;46(9):1888-95. Epub 2005 Jul 1.

21.

Paraoxonase 1 (PON1) status and risk of insecticide exposure.

Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG.

J Biochem Mol Toxicol. 2005;19(3):182-3. No abstract available.

PMID:
15977192
22.

Determination of paraoxonase 1 status and genotypes at specific polymorphic sites.

Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE.

Curr Protoc Toxicol. 2004 May;Chapter 4:Unit4.12. doi: 10.1002/0471140856.tx0412s19.

PMID:
20945303
23.

Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease.

Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ, Furlong CE.

Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1465-71. Epub 2003 Jun 12.

PMID:
12805074
24.

Expression of human paraoxonase (PON1) during development.

Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE.

Pharmacogenetics. 2003 Jun;13(6):357-64.

PMID:
12777966
25.

Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.

Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE.

Pharmacogenetics. 2003 May;13(5):291-5.

PMID:
12724622
26.

Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity.

Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE.

Biomarkers. 2003 Jan-Feb;8(1):1-12. Review.

PMID:
12519632
27.

Vitamin C and E intake is associated with increased paraoxonase activity.

Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE.

Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1329-33.

PMID:
12171796
28.

Polymorphisms in the human paraoxonase (PON1) promoter.

Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE.

Pharmacogenetics. 2001 Feb;11(1):77-84.

PMID:
11207034
29.

Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds.

Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE.

Pharmacogenetics. 2000 Dec;10(9):767-79.

PMID:
11191881
30.

Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype.

Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE.

Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2441-7.

PMID:
11073850
31.

The PON1 gene and detoxication.

Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, Lusis AJ, Costa LG.

Neurotoxicology. 2000 Aug;21(4):581-7.

PMID:
11022865
32.

Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype.

Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE.

Pharmacogenetics. 2000 Jul;10(5):453-60.

PMID:
10898114
33.

Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1).

Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG.

Neurotoxicology. 2000 Feb-Apr;21(1-2):91-100. Review.

PMID:
10794389
34.

Determination of paraoxonase (PON1) status requires more than genotyping.

Richter RJ, Furlong CE.

Pharmacogenetics. 1999 Dec;9(6):745-53.

PMID:
10634137
35.

The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism.

Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE.

Chem Biol Interact. 1999 May 14;119-120:429-38. Review.

PMID:
10421480
36.

Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism.

Furlong CE, Li WF, Costa LG, Richter RJ, Shih DM, Lusis AJ.

Neurotoxicology. 1998 Aug-Oct;19(4-5):645-50.

PMID:
9745924
37.

The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin.

Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE.

Nat Genet. 1996 Nov;14(3):334-6.

PMID:
8896566
38.

Paraoxonase genotypes, lipoprotein lipase activity, and HDL.

Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD.

Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1243-9.

PMID:
8857920
39.

Apolipoprotein J is associated with paraoxonase in human plasma.

Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA.

Biochemistry. 1994 Jan 25;33(3):832-9.

PMID:
8292612
40.

Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification.

Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline C, Crabb JW, et al.

Chem Biol Interact. 1993 Jun;87(1-3):35-48. Review.

PMID:
8393745
41.

Purification of rabbit and human serum paraoxonase.

Furlong CE, Richter RJ, Chapline C, Crabb JW.

Biochemistry. 1991 Oct 22;30(42):10133-40.

PMID:
1718413
42.

Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence.

Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE.

Biochemistry. 1991 Oct 22;30(42):10141-9.

PMID:
1657140
43.

Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats.

Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE.

Toxicol Appl Pharmacol. 1990 Mar 15;103(1):66-76.

PMID:
1690462
44.

Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase.

Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG.

Anal Biochem. 1989 Aug 1;180(2):242-7.

PMID:
2479288
45.
46.

Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin.

Ortigoza-Ferado J, Richter RJ, Hornung SK, Motulsky AG, Furlong CE.

Am J Hum Genet. 1984 Mar;36(2):295-305.

47.

Renaturation and identification of periplasmic proteins in two-dimensional gels of Escherichia coli.

Copeland BR, Richter RJ, Furlong CE.

J Biol Chem. 1982 Dec 25;257(24):15065-71.

Supplemental Content

Loading ...
Support Center